<DOC>
	<DOCNO>NCT01106248</DOCNO>
	<brief_summary>The purpose study ass whether eribulin mesylate ( E7389 ) impact electrocardiogram ( ECG ) focus cardiac repolarization , measure QT/QTc interval well pharmacokinetic-pharmacodynamic ( PK/PD ) analysis .</brief_summary>
	<brief_title>QT Interval Prolongation Study Eribulin Mesylate ( E7389 ) Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This open-label , multicenter , single arm QT Interval prolongation study eribulin mesylate ( E7389 ) patient advance solid tumor .</detailed_description>
	<criteria>Personal history unexplained syncope within last year prior entry 1 . Patients histologically cytologically confirm advanced solid tumor progress follow standard therapy standard therapy exists ( include surgery radiation therapy ) . 2 . Resolution chemotherapy radiationrelated toxicity Grade 1 severity low , except stable sensory neuropathy &lt; /= Grade 2 alopecia . 3 . Age &gt; /= 18 year . 4 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 . 5 . Patients must sinus rhythm QRS &lt; 120msec . 6 . Adequate renal function evidence serum creatinine &lt; /= 2.0 mg/dL calculate creatinine clearance &gt; /= 40 mL/min per Cockcroft Gault formula . 7 . Adequate bone marrow function evidence absolute neutrophil count ( ANC ) &gt; /= 1.5 x 10^9/L , hemoglobin &gt; /= 10.0 g/dL ( hemoglobin &lt; 10.0 g/dL acceptable correct growth factor transfusion ) , platelet count &gt; /= 100 x 10^9/L . 8 . Adequate liver function evidence bilirubin &gt; /= 1.5 time upper limit normal ( ULN ) alkaline phosphatase , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) &lt; /= 3 x ULN ( case liver metastasis &lt; /= 5 x ULN ) , unless bone metastasis , case liver specific alkaline phosphatase must separate total use ass liver function instead total alkaline phosphatase . 9 . Patients willing able comply study protocol duration study . 10 . Written inform consent prior studyspecific screening procedure understand patient may withdraw consent time without prejudice . 1 . Patients receive follow treatment within specified period start treatment eribulin mesylate : Chemotherapy , radiation biological therapy within three week Hormonal therapy within one week Any investigational drug within four week 2 . Have radiation therapy encompass &gt; 30 % bone marrow . 3 . Have receive prior treatment mitomycin C nitrosourea . 4 . Pulmonary lymphangitic involvement result pulmonary dysfunction require active treatment , include use oxygen . 5 . Patients brain subdural metastasis eligible , unless complete local therapy discontinue use corticosteroid indication least 4 week start treatment study . Any sign ( e.g . radiologic ) and/or symptom brain metastasis must stable least 4 week . 6 . Patients meningeal carcinomatosis . 7 . Significant cardiovascular impairment ( history congestive heart failure &gt; NYHA grade II , unstable angina myocardial infarction within past six month , serious cardiac arrhythmia ) . 8 . Patients mark baseline prolongation QT/QTc interval ( QTc interval &gt; 500 msec ) . 9 . Patients history additional risk factor Torsades de pointes ( e.g. , heart failure , cardiac ischemia , recent Myocardial Infarction ( MI ) , family history Long QT Syndrome ) . 10 . Patients uncontrolled metabolic disorder ( e.g hypokalemia , hypercalcemia hypomagnesemia ) entry study . 11 . Patients treated antiarrythmic drug medication prolong QT/QTc , discontinue prior entry study phase . 12 . Patients implantable pacemaker automatic implantable cardioverter defibrillator ( AICD ) . 13 . .Bradycardia ( define &lt; /= 50 beats/minute ) . 14 . Personal history unexplained syncope within last year prior entry study . 15 . Patients significant disease disorder , Investigator 's opinion , exclude patient study . 16 . Patients receive anticoagulant therapy warfarin related compound , line patency , change heparinbased therapy , eligible . If patient continue minidose warfarin , prothrombin time ( PT ) international normalize ratio ( INR ) must closely monitor . 17 . Women pregnant breastfeeding ; woman childbearing potential either positive pregnancy test screening pregnancy test ; woman childbearing potential unless ( 1 ) surgically sterile ( 2 ) use adequate measure contraception opinion Investigator . Perimenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . 18 . Severe/uncontrolled intercurrent illness/infection . 19 . Patients organ allograft require immunosuppression . 20 . Patients know positive HIV status . 21 . Patients prior malignancy , carcinoma situ cervix , nonmelanoma skin cancer , unless prior malignancy diagnose definitively treat &gt; /= 5 year previously subsequent evidence recurrence . 22 . Patients preexist neuropathy &gt; Grade 2 . 23 . Patients hypersensitivity halichondrin B and/or halichondrin B chemical derivative . 24 . Patients participate prior eribulin mesylate clinical trial . 25 . Patients pericardial effusion pericardial metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>tumor</keyword>
</DOC>